Close

Aralez Pharma (ARLZ) Announces U.S. Launch of YOSPRALA

Go back to Aralez Pharma (ARLZ) Announces U.S. Launch of YOSPRALA

Guggenheim Remains Positive on Aralez Pharma (ARLZ) Amid Toprol-XL Deal with AstraZeneca (AZN)

October 4, 2016 8:52 AM EDT

Guggenheim affirms Aralez Pharmaceuticals Inc. (Nasdaq: ARLZ) with a Buy rating and $12 price target after the company announced it will acquire the U.S. rights... More

Aralez Pharma (ARLZ) to Acquire Toprol-XL U.S. Rights from AstraZeneca (AZN)

October 4, 2016 6:06 AM EDT

Aralez Pharmaceuticals Inc. (Nasdaq: ARLZ) announced it will acquire the U.S. rights to Toprol-XL (metoprolol succinate) and its Authorized Generic (AG) pursuant to an agreement entered into between AstraZeneca and Aralez Pharmaceuticals Trading DAC, a subsidiary of Aralez. Toprol-XL is a cardioselective beta-blocker indicated for the treatment of hypertension, alone or in combination with other antihypertensives; the long term treatment of angina pectoris and treatment of stable, symptomatic (NYHA class II or III) heart failure of... More